CCCC (C4 Therapeutics) Dividend-Payout-to-FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CCCC C4 Therapeutics Inc CCCC
49 GF Score
Price $4.12
GF Value $2.05
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is C4 Therapeutics Dividend-Payout-to-FFO?

Dividend-Payout-to-FFO only applies to REITs.

CCCC
49GF Score
C4 Therapeutics Inc CCCC
Dividend-Payout-to-FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is C4 Therapeutics (CCCC) Overvalued in 2026?

Based on GuruFocus' analysis, C4 Therapeutics stock appears to be overvalued. The current stock price of $4.12 is trading 100.7% above its estimated GF Value™ of $2.05. GuruFocus considers C4 Therapeutics to be Significantly Overvalued.

Key valuation signals for CCCC:

  • Dividend-Payout-to-FFO:
  • GF Value™: $2.05 vs. price of $4.12 (100.7% above fair value)
  • GF Score™: 49/100 with 7 warning signs

No single metric tells the full story. See the CCCC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

C4 Therapeutics Business Description

Address 490 Arsenal Way, Suite 120, Watertown, MA, USA, 02472
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.
49GF Score

Get the complete analysis for CCCC

Dividend-Payout-to-FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.12
Price
$2.05
GF Value